Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.36 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.36 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.36 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25400709 | 0.90 | NPC1 (0.42) | NPC1RAB9AMAPTLMNAL3MBTL1 | |
| SCHEMBL28758982 | 0.90 | LGALS9 (0.41) | LMNABCHELGALS3LGALS9LGALS1 | |
| SCHEMBL28562523 | 0.88 | NPC1 (0.40) | NPC1RAB9AMAPTLMNAL3MBTL1 | |
| SCHEMBL28427525 | 0.88 | NPC1 (0.40) | NPC1RAB9AMAPTLMNAL3MBTL1 | |
| SCHEMBL28400811 | 0.86 | NPC1 (0.39) | NPC1RAB9AMAPTLMNAL3MBTL1 | |
| SCHEMBL28716111 | 0.83 | NPC1 (0.40) | NPC1RAB9AMAPTLMNAL3MBTL1 | |
| SCHEMBL25401960 | 0.81 | NPC1 (0.43) | NPC1RAB9AMAPTLMNAL3MBTL1 | |
| SCHEMBL10062003 | 0.78 | LGALS9 (0.40) | LMNABCHELGALS3LGALS9LGALS1 | |
| SCHEMBL28426427 | 0.78 | NPC1 (0.40) | NPC1RAB9AMAPTLMNAL3MBTL1 | |
| SCHEMBL17560689 | 0.78 | NPC1 (0.40) | NPC1RAB9AMAPTLMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024107859-A1 | CYCLOPENTENE-OXYMETHYLENE PHOSPHONAMIDATES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | ROME THERAPEUTICS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023178133-A9 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2023178133-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| CN-114008064-A | Novel phosphate ester compound having pyrrolopyrimidine skeleton or pharmaceutically acceptable salt thereof | 大鹏药品工业株式会社 | 2022-02-01 | — | — | CN | disclosed |
| CN-113993877-A | Novel carbonate compound having pyrrolopyrimidine skeleton or pharmaceutically acceptable salt thereof | 大鹏药品工业株式会社 | 2022-01-28 | — | — | CN | disclosed |
| WO-2018089786-A1 | ATG7 INHIBITORS AND THE USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | NPC1 1180/4885RAB9A 2105/4885MAPT 147/4885 |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | NPC1 1180/4885RAB9A 2105/4885MAPT 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.